Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
Applications include detailed scientific rationale and supporting clinical evidence
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
Patients can now get the starting 2.5 mg dose for $299 per month
This move positions the U.S.-based consumer healthcare company for a significantly larger role in the rapidly expanding at-home and retail diagnostic testing market
Subscribe To Our Newsletter & Stay Updated
